Skip to main content

A randomized phase 2 trial of veliparib (V), radiotherapy (RT) and temozolomide (TMZ) in patients (pts) with unmethylated MGMT (uMGMT) glioblastoma (GBM): Feasibility and safety outcomes (the VERTU study).

Publication ,  Conference
Khasraw, M; McDonald, KL; Rosenthal, M; Lwin, Z; Ashley, DM; Wheeler, H; Barnes, E; Koh, E-S; Foote, MC; Buckland, M; Fisher, L; Leonard, R ...
Published in: Journal of Clinical Oncology
May 20, 2018

Duke Scholars

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2018

Volume

36

Issue

15_suppl

Start / End Page

2045 / 2045

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Khasraw, M., McDonald, K. L., Rosenthal, M., Lwin, Z., Ashley, D. M., Wheeler, H., … Simes, J. (2018). A randomized phase 2 trial of veliparib (V), radiotherapy (RT) and temozolomide (TMZ) in patients (pts) with unmethylated MGMT (uMGMT) glioblastoma (GBM): Feasibility and safety outcomes (the VERTU study). In Journal of Clinical Oncology (Vol. 36, pp. 2045–2045). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2018.36.15_suppl.2045
Khasraw, Mustafa, Kerrie Leanne McDonald, Mark Rosenthal, Zarnie Lwin, David M. Ashley, Helen Wheeler, Elizabeth Barnes, et al. “A randomized phase 2 trial of veliparib (V), radiotherapy (RT) and temozolomide (TMZ) in patients (pts) with unmethylated MGMT (uMGMT) glioblastoma (GBM): Feasibility and safety outcomes (the VERTU study).” In Journal of Clinical Oncology, 36:2045–2045. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.2045.
Khasraw M, McDonald KL, Rosenthal M, Lwin Z, Ashley DM, Wheeler H, et al. A randomized phase 2 trial of veliparib (V), radiotherapy (RT) and temozolomide (TMZ) in patients (pts) with unmethylated MGMT (uMGMT) glioblastoma (GBM): Feasibility and safety outcomes (the VERTU study). In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. 2045–2045.
Khasraw, Mustafa, et al. “A randomized phase 2 trial of veliparib (V), radiotherapy (RT) and temozolomide (TMZ) in patients (pts) with unmethylated MGMT (uMGMT) glioblastoma (GBM): Feasibility and safety outcomes (the VERTU study).Journal of Clinical Oncology, vol. 36, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2018, pp. 2045–2045. Crossref, doi:10.1200/jco.2018.36.15_suppl.2045.
Khasraw M, McDonald KL, Rosenthal M, Lwin Z, Ashley DM, Wheeler H, Barnes E, Koh E-S, Foote MC, Buckland M, Fisher L, Leonard R, Hall M, Yip S, Simes J. A randomized phase 2 trial of veliparib (V), radiotherapy (RT) and temozolomide (TMZ) in patients (pts) with unmethylated MGMT (uMGMT) glioblastoma (GBM): Feasibility and safety outcomes (the VERTU study). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. 2045–2045.

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2018

Volume

36

Issue

15_suppl

Start / End Page

2045 / 2045

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences